Xanthine derivative, pentoxifylline (PTX), has been recently shown to exert a protective effects in certain animal models of autoimmunity, including diabetes in NOD mice. In the present study, the immunomodulatory potential of PTX was investigated in autoimmune diabetes induced by multiple low doses of streptozotocin (MLD-SZ) 
INTRODUCTION
Pentoxifylline (PTX) [3,7-dimethyl-l-(5-oxohexyl) xanthine] is the drug that is widely used for the treatment of vascular disorders. However, there are new evidences for the potential therapeutic properties of this compound. Preclinical studies in laboratory rodents have shown that PTX and related compounds may favorably influence the course of experimental inflammatory and autoimmune disorders, such as autoimmune encephalomyelitis (Rott et al., 1993; Nataf et al., 1993) , meningitis (Saez-Lorens et al., 1990 ) and autoimmune neuritis (Constantinescu et al., 1996 (Like and Rossini, 1976; Luki et al., 1991a; Kolb and Kroncke, 1993 (Figure 2 ). In susceptible DA rats small infiltrates were rarely seen (grade 1) and infiltrating cells were scattered throughout the islets (Figure 3 ). In both species mononuclear infiltration was accompanied with initial necrotic changes and slight edema in the connective spaces around the islets and blood vessels (Figures 2 and 3) . However, the majority of the islets were still well preserved and free from infiltration, thus suggesting asynchronous process. Immunohistochemical analysis in rats confirmed our earlier findings (Luki et al., 1991 MLD-SZ-induced autoimmune diabetes appears to be a T cell-dependent disease (Elliot et al., 1997) . Since T cell reactivity is regulated by APCs, in animal models of IDDM it has been postulated that the functional state of APCs is responsible for the progression of Thl-dependent destructive insulitis (Rothe and Kolb, 1998 ). It appears that by stimulating Th cells (Cockfield et al., 1989) , MLD-SZ caused up-regulation of IFN-y and MHC Class II expression that are required to propagate the autoimmune process leading to IDDM. IFN-7 production can be reduced by treatment with PTX (Figure 4 and (Corbett et al., 1992; Kaneto et al., 1995; Corbett and McDaniel, 1995) . Since PTX has been found to be able to inhibit the release of inflammatory cytokines (Van-Furth et al., 1994; Rieneck et al., 1995) , and favor Th2 response (Liblau et al., 1995) , the drug may indirectly interfere with the induction of iNOS. It fits well with the finding that PTX reduces deleterious effects of TNF-ot on human islets (Ariasdiaz et al., 1995 Immunohistochemical analysis was performed from a snap-frozen sections, using indirect immunoperoxidase staining as described previously (Stoid-Grujiid et al., 1999 
